

The Study of Serum Chemerin in patients with Polycystic Ovaries Syndrome (PCOS) and its relation to insulin resistance

Thesis

*Submitted for partial fulfillment of MD degree
In Internal Medicine*

By

Bahaa Mahmoud Mohamed Taha
Master degree of internal medicine

Supervised of

Doctor/ Mohamed Reda Halawa
*Professor of Internal medicine and Endocrinology
Faculty of Medicine – Ain Shams University*

Doctor/ Rania Sayed Abd El Baky
*Professor of Internal Medicine and Endocrinology
Faculty of Medicine - Ain Shams University*

Doctor/ Yara Mohamed Eid
*Professor of Internal Medicine and Endocrinology
Faculty of Medicine - Ain Shams University*

Doctor/ Merihan Samy Nasr
*Associate professor of Internal Medicine and Endocrinology
Faculty of Medicine - Ain Shams University*

Doctor/ Laila Mahmoud Hendawy
*Associate professor of Internal Medicine and Endocrinology
Faculty of Medicine – Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبِقَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I was honored to work under the supervision of **Doctor/ Mohamed Reda Halawa**, Professor of Internal medicine and Endocrinology, Faculty of Medicine - Ain Shams University, for his vital assistance and unlimited co-operation. he had generously offered me much of his time, precious advice and variable guidance throughout this work.*

*I wish to express my deepest thanks and gratitude to **Doctor/ Rania Sayed Abd El Baky**, professor of Internal Medicine and Endocrinology, Faculty of Medicine - Ain Shams University, for her close supervision, great efforts and constant encouragement. She had scarified a lot of her busy time to teach me and revise over step of this thesis.*

*I would like to express my sincere thanks to **Doctor/ Yara Mohamed Eid**, professor of Internal Medicine and Endocrinology, Faculty of Medicine - Ain Shams University, who kindly offered me much of her time, experience, valuable help and effort.*

*I would like to express my deepest thanks to **Doctor/ Merihan Samy Nasr**, Associate professor of Internal Medicine and Endocrinology, Faculty of Medicine-Ain Shams University, who kindly offered me much of her support, experience, cooperation and effort.*

*I would like to express my sincere thanks to **Doctor/ Laila Mahmoud Hendaawy**, Associate professor of Internal Medicine and Endocrinology, Faculty of Medicine – Ain Shams University, who kindly offered me much of her time, experience, valuable help and effort to finish this work.*

*I would like to express my sincere thanks to **Doctor/ Mamoud Fathy Ahmed**, clinical pathology Faculty of Medicine – Ain Shams University, for his great effort in our laboratory study*

To my family, all my colleagues and all those who helped me in this work, I am so thankful for their support and co-operation.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Bahaa Mahmoud Mohamed Taha

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations.....	iv
Introduction.....	1
Aim of the Work	3
<i>Review of Literature</i>	
• Polycystic ovarian syndrome	4
• Insulin resistance	19
• Adipose tissue is an endocrine organ.....	33
• Chemerin	58
Subjects and Methods.....	74
Results	85
Discussion.....	115
Summary.....	121
Conclusion	125
Recommendation.....	126
References.....	127
Arabic Summary	-

List of Tables

Table No.	Title	Page No.
Table (1):	Criteria for diagnosis of metabolic syndrome according to a joint statement of IDF, AHA/NHLBI, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity adabted from	30
Table (2):	Comparison between control group and PCO group regarding demographic data and clinical data	87
Table (3):	Comparison between control group and PCO group regarding laboratory data.....	88
Table (4):	Comparison between the four studied groups regarding demographic data and clinical data	93
Table (5):	Comparison between the four studied groups regarding laboratory data.....	95
Table (6):	Post Hoc analysis (obese control Vs lean control).....	98
Table (7):	Post Hoc analysis (lean PCO Vs lean control)	98
Table (8):	Post Hoc analysis (Obese PCO Vs lean control)	99
Table (9):	Post Hoc analysis (lean PCO Vs obese control)	99
Table (10):	Post Hoc analysis (Obese PCO Vs obese control).....	100
Table (11):	Post Hoc analysis (Obese PCO Vs lean PCO).....	100
Table (12):	Correlation between chemerin level and the other studied parameters in control group.....	101
Table (13):	Correlation between chemerin level and the other studied parameters in PCO group	102
Table (14):	Correlation of chemerin level with the other studied parameters in lean PCO group	108
Table (15):	Correlation of chemerin level with the other studied parameters in obese PCO group.....	112

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Comparison between control group and PCO group regarding presence of hirsutism.....	88
Figure (2):	Comparison between control group and PCO group regarding fasting sugar.....	90
Figure (3):	Comparison between control group and PCO group regarding fasting insulin.....	90
Figure (4):	Comparison between control group and PCO group regarding HOMA IR.....	91
Figure (5):	Comparison between control group and PCO group regarding total testosterone	91
Figure (6):	Comparison between control group and PCO group regarding chemerin	92
Figure (7):	Comparison between the four studied groups regarding presence of hirsutism.....	94
Figure (8):	Comparison between the four studied groups regarding fasting insulin.....	96
Figure (9):	Comparison between the four studied groups regarding HOMA IR.....	96
Figure (10):	Comparison between the four studied groups regarding total testosterone.	97
Figure (11):	Comparison between the four studied groups regarding chemerin level.....	97
Figure (12):	Positive Correlation between chemerin level and BMI level in control group.	103
Figure (13):	Positive Correlation between chemerin level and fasting insulin level in control group.	103
Figure (14):	Positive Correlation between chemerin level and HOMA IR level in control group.	104
Figure (15):	Positive Correlation between chemerin level and BMI level in PCO group.	105
Figure (16):	Positive Correlation between chemerin level and fasting sugar level in PCO group.....	105
Figure (17):	Positive Correlation between chemerin level and fasting insulin level in PCO group.....	106
Figure (18):	Positive Correlation between chemerin level and HOMA IR level in PCO group.....	106

List of Figures (Cont.)

Fig. No.	Title	Page No.
Figure (19):	Positive Correlation between chemerin level and total testosterone level in PCO group.	107
Figure (20):	Positive Correlation between chemerin and BMI in lean PCO group.	109
Figure (21):	Positive Correlation between chemerin and fasting sugar in lean PCO group.	109
Figure (22):	Positive Correlation between chemerin and fasting insulin in lean PCO group.	110
Figure (23):	Positive Correlation between chemerin and HOMA IR in lean PCO group.	110
Figure (24):	Positive Correlation between chemerin and total testosterone in lean PCO group.	111
Figure (25):	Positive Correlation between chemerin and fasting sugar in obese PCO group.	113
Figure (26):	Positive Correlation between chemerin and fasting insulin in normal obese PCO group.	113
Figure (27):	Positive Correlation between chemerin and HOMA IR in obese PCO group.	114
Figure (28):	Positive Correlation between chemerin and total testosterone in obese PCO group.	114

List of Abbreviations

Abb.	Full term
A-FABP	ADIPOCYTE fatty-acid-binding protein
AHA	American Heart Association
BMI	Body mass index
CCNB2	Cyclin B2
CCRL2.....	Chemokine (C-C motif) receptor-like 2
CHD	Coronary heart disease
CMKLR1	Chemokine receptor like 1
CVD	Cardiovascular disease
DCs.....	Dendritic cells
ER.....	Endoplasmic reticulum
ERK	Extracellular signal-regulated kinases
FFA.....	Free fatty acids
GPR1	G protein-coupled receptor
HDL	High-density lipoprotein
HTR2B	Hydroxytryptamine receptor 2B
IL13RA2.....	Interleukin-13 receptor alpha2
IL-6.....	Interleukin-6
IR	Insulin resistance
LA-ratio	Leptin / adiponectin levels
LDL	Low-density lipoprotein
LH	Luteinizing hormone
MAPK	Mitogen-activated protein kinase
MCP-1	Monocytes chemo-attractant protein-1
MS	Metabolic syndrome
NHLBI	National Heart, Lung and Blood Institute
PAH	Pulmonary arterial hypertension
PCI	Percutaneous coronary intervention

List of Abbreviations (Cont.)

Abb.	Full term
PCOS	Polycystic ovary syndrome
PI3K	Phosphatidylinositol 3 kinase
PVAT	Perivascular adipose tissue
RAAS	Renin-angiotensin-aldosterone system
RARRES2	Retinoic acid receptor responder 2
RBP4	Retinol binding protein 4
SAT	Subcutaneous adipose tissue
SLC16A	Solute linked carrier 16A
SNS	Sympathetic nervous system
SNS	Sympathetic nervous system
SSC	Squamous cell carcinoma
STEMI	ST segment elevation

INTRODUCTION

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances, reflecting on a clinical presentation dominated by manifestations of hyperandrogenism, which generate short and long term consequences on female health (*Teede et al., 2010*).

The manifestations of PCOS are not confined to the gynecological sphere; women afflicted by this disease show an increased prevalence of several comorbidities, including obesity dyslipidemia, hypertension, metabolic syndrome (MS) and type 2 diabetes mellitus (DM2) in comparison with women without PCOS (*Wild, 2002*).

Several studies have pinpointed insulin resistance (IR) as the fundamental link associating PCOS and obesity (*Reaven, 2011*) though IR may be present in PCOS independently of obesity (*Toprak et al., 2001*). IR, defined as a metabolic state characterized by a decrease in cellular ability to respond to insulin signaling, appears to be an essential pathophysiologic mechanism in the development of all metabolic complications of PCOS (*Apridonidze et al., 2005*).

Adipose tissue represent an active endocrine organ that release a large number of bioactive mediators (adipokines) that signal to organs of metabolic importance including brain, liver, skeletal muscle and immune sysem thereby modulating

homeostasis, blood pressure, lipid, glucose metabolism, inflammation and atherosclerosis (*Rabe et al., 2008*).

Chemerin is an adipokine that has been associated with autocrine /paracrine signaling for adipocytes differentiation and maturation, in addition, it can regulate glucose uptake and stimulate lipolysis via phosphorylation of some intermediates in human adipocytes which are involved in mediating lipolysis and insulin signaling pathway (*Goralski et al., 2007*).

Several studies suggested that it could induce insulin resistance in skeletal muscle cells. Thereby it is thought to be elevated in adipose tissue of type 2 diabetic patients. Furthermore, chemerin levels have been reported to be associated with components of the metabolic syndrome, including elevated levels of body mass index, plasma triglycerides and blood pressure (*Bozaoglu et al., 2007*).

AIM OF THE WORK

To determine serum chemerin level and its relation to insulin resistance in patients with polycystic ovary syndrome.

Chapter 1

POLYCYSTIC OVARIAN SYNDROME

The polycystic ovary syndrome (PCOS) is a disorder that is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphologic features. As defined by the diagnostic criteria of the National Institutes of Health (i.e., hyperandrogenism plus ovulatory dysfunction), “classic” polycystic ovary syndrome affects 6 to 10% of women of reproductive age, but the prevalence may be twice as high under the broader Rotterdam criteria (*Dumesic et al., 2015*).

This complex polygenic disorder has environmental influences (e.g., those that contribute to obesity) (*Dumesic et al., 2015*).

Many studies suggest that inherent abnormalities of ovarian steroidogenesis and follicular development play a role in the polycystic ovary syndrome. The syndrome is also associated with persistently rapid gonadotropin-releasing hormone pulses, an excess of luteinizing hormone, and insufficient follicle-stimulating hormone (FSH) secretion, which contribute to excessive ovarian androgen production and ovulatory dysfunction. In addition, many women with the polycystic ovary syndrome have insulin resistance, and compensatory hyperinsulinemia enhances ovarian (and adrenal) androgen production and increases androgen bioavailability

through reduced levels of sex hormone-binding globulin. Genomewide association studies implicate many genes, including those for gonadotropin receptors, the beta subunit of FSH, insulin receptor, differentially expressed in normal and neoplastic cells domain-containing protein 1A (*DENND1A*), and thyroid adenoma-associated protein (*THADA*). “Developmental programming” through environmental or hormonal imprinting may also contribute to the development of the polycystic ovary syndrome. Various pathophysiological factors may play different relative roles in individual patients (*Dumesic et al., 2015*).

PCOS and cardiometabolic effects

The polycystic ovary syndrome is associated with cardiometabolic abnormalities and possibly an increased risk of cardiovascular disease (*Wild et al., 2010*). Among women with this syndrome, 50 to 80% are obese (*Dumesic et al., 2015*). Impaired glucose tolerance is reported in 30 to 35% of U.S. women with classic polycystic ovary syndrome, and type 2 diabetes mellitus is reported in 8 to 10%; the risk of these conditions is influenced by age, adiposity, and a family history of diabetes (*Ehrmann et al., 1999*). Women with the polycystic ovary syndrome have lower high-density lipoprotein cholesterol and higher triglyceride and low-density lipoprotein (LDL) cholesterol levels than women without the syndrome. Differences in LDL cholesterol levels are at least partly independent of differences in BMI (*Wild et al., 2011*).

PCOS and insulin resistance

Fasting insulin level was found to be elevated even in PCOS women without evident metabolic syndrome (MS) and it was suggested that the elevated insulin contributes to the elevated androgen production by the ovaries and other complications. Several studies indicated that as much as 60-95% of PCOS women show insulin resistance (IR), which becomes aggravated if accompanied by increased abdominal fat (*Stepito et al., 2013*). However, IR in PCOS women cannot be completely explained by abdominal adiposity and several other factors such as defective glucose, lipid and steroid metabolism, dysregulated insulin signaling and altered adipokine secretion also likely contribute to IR (*Dumesic et al., 2015*). IR and elevated circulating insulin were found to stimulate the theca cells of ovaries to produce and secrete androgens and also to enhance the responsiveness of ovaries to luteinizing hormone (LH) to produce androgens (*Polak et al., 2017*). In fact, it has been noted that even in the absence of overt obesity, there can be preferential deposition of fat intra-abdominally in PCOS women with normal body weight. This intra-abdominal fat leads to elevated number of small subcutaneous abdominal adipocytes, which contribute to impaired insulin action and thus functional IR and hyperandrogenism (*Dumesic et al., 2016*). Decreased ability of intra-abdominal subcutaneous adipocytes to store and sequester fat in normal weight PCOS women leads to ectopic fat deposition in other tissues such as muscle and